HP&M’s Larry Houck A Panelist at FDLI’s Cannabis Regulation Conference
FDA Law Blog: Biosimilars
MARCH 10, 2024
Last August the Food and Drug Administration (“FDA”)/Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule cannabis from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. By doing so, FDA/HHS believe that cannabis no longer meets schedule I criteria but does not meet schedule II criteria either.
Let's personalize your content